Enanta Pharmaceuticals to Participate in Two Investor Conferences in NovemberBusiness Wire • 11/22/22
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 11/21/22
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ETBusiness Wire • 11/21/22
Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022Business Wire • 11/14/22
Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19Business Wire • 11/09/22
Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022Business Wire • 10/19/22
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial VirusBusiness Wire • 10/17/22
Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial VirusBusiness Wire • 10/03/22
Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV SymposiumBusiness Wire • 09/29/22
Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV SymposiumBusiness Wire • 09/22/22
New Preclinical Data for EDP-235, Enanta's Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022Business Wire • 09/07/22
Enanta Pharmaceuticals to Participate in Two Investor Conferences in SeptemberBusiness Wire • 09/01/22
Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q3 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 08/08/22
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ETBusiness Wire • 08/08/22
Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022Business Wire • 08/01/22
Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19Business Wire • 07/29/22
Earnings Preview: Enanta Pharmaceuticals (ENTA) Q3 Earnings Expected to DeclineZacks Investment Research • 07/28/22
Enanta Pharmaceuticals (ENTA) Stock Jumps 10.1%: Will It Continue to Soar?Zacks Investment Research • 06/24/22
Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022Business Wire • 06/08/22